211 related articles for article (PubMed ID: 8540753)
1. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.
Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T
J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice.
Yoshida Y; Yamamura J; Sato H; Koyasu M; Obara Y; Sekiguchi H; Kawana T; Shiraki K
J Dermatol Sci; 1996 Dec; 13(3):237-41. PubMed ID: 9023706
[TBL] [Abstract][Full Text] [Related]
5. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
Lawetz C; Liuzzi M
Antiviral Res; 1998 Jul; 39(1):35-46. PubMed ID: 9754948
[TBL] [Abstract][Full Text] [Related]
6. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of eugenol on human herpesvirus.
Benencia F; Courrèges MC
Phytother Res; 2000 Nov; 14(7):495-500. PubMed ID: 11054837
[TBL] [Abstract][Full Text] [Related]
8. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
10. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
11. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.
Schuhmacher A; Reichling J; Schnitzler P
Phytomedicine; 2003; 10(6-7):504-10. PubMed ID: 13678235
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice.
Park HJ; Kurokawa M; Shiraki K; Nakamura N; Choi JS; Hattori M
Biol Pharm Bull; 2005 Dec; 28(12):2258-62. PubMed ID: 16327161
[TBL] [Abstract][Full Text] [Related]
13. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV
mBio; 2019 May; 10(3):. PubMed ID: 31088925
[TBL] [Abstract][Full Text] [Related]
14. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
16. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.
Prichard MN; Kern ER; Hartline CB; Lanier ER; Quenelle DC
Antimicrob Agents Chemother; 2011 Oct; 55(10):4728-34. PubMed ID: 21788472
[TBL] [Abstract][Full Text] [Related]
17. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents.
Moss N; Beaulieu P; Duceppe JS; Ferland JM; Gauthier J; Ghiro E; Goulet S; Grenier L; Llinas-Brunet M; Plante R
J Med Chem; 1995 Sep; 38(18):3617-23. PubMed ID: 7658449
[TBL] [Abstract][Full Text] [Related]
18. Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice.
Bhutta MS; Sausen DG; Reed KM; Gallo ES; Hair PS; Lassiter BP; Krishna NK; Cunnion KM; Borenstein R
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452288
[TBL] [Abstract][Full Text] [Related]
19. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo.
Liuzzi M; Déziel R; Moss N; Beaulieu P; Bonneau AM; Bousquet C; Chafouleas JG; Garneau M; Jaramillo J; Krogsrud RL
Nature; 1994 Dec; 372(6507):695-8. PubMed ID: 7990963
[TBL] [Abstract][Full Text] [Related]
20. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
